Guest guest Posted January 12, 2011 Report Share Posted January 12, 2011 Dear Members, Idraparinux (undergoing phase III clinical testing as of 2004) is a more highly sulfated derivative of fondaparinux that has a half-life of 5 to 6 days; the lack of a suitable antidote may limit its clinical application. Regards,Dr. Vijaya Chaudhari.JR-3,Dept. of Pharmacology,Government Medical College, Nagpur. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.